Tag: Carole Spangler Vaughn

Rapamycin Holdings Becomes Emtora Biosciences, Gains New CEO
Articles, Featured

Rapamycin Holdings Becomes Emtora Biosciences, Gains New CEO

San Antonio-based Rapamycin Holdings, Inc. announced its rebranding Tuesday as Emtora Biosciences with Dr. Carole Spangler Vaughn as its new chief executive officer. Dan Hargrove recruited Spangler Vaughn as his replacement after hiring her as a consultant for the privately-held drug development company about six months ago. The drug company is commercializing a ground-breaking cancer prevention drug, eRapa™, a proprietary reformulation of the generic drug Rapamycin. The changes reflect the company's goal to get the drug through the regulatory approval process faster for a quicker market launch. “I’ve brought drugs to the market before,” Spangler Vaughn told Startups San Antonio. “With my background and experience, I can ask detailed questions about the science, then ask about the dr...